Description
NLG919 is an inhibitor of indoleamine-2,3-dioxygenase (IDO). This compound displays anticancer chemotherapeutic activity, prolonging survival rates in animal models of glioblastoma.
NLG919
Product ID N4524
Cas No. 1402836-58-1
Purity ≥98%
| Product Unit Size | Cost | Quantity | Stock |
|---|
Product Info
| Cas No. | 1402836-58-1 |
|---|---|
| Purity | ≥98% |
| Formula | C18H22N2O |
| Formula Wt. | 282.39 |
| IUPAC Name | 1-Cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethanol |
| Solubility | Ethanol 30 mg/mL (106.23 mM) DMSO 15 mg/mL warmed (53.11 mM) Water Insoluble |
Shipping and Storage
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
Downloads
| MSDS | |
|---|---|
| Info Sheet |
References
Vacchelli E, Aranda F, Eggermont A, et al. Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology. 2014 Dec 15;3(10):e957994. PMID: 25941578.
Li M, Bolduc AR, Hoda MN, et al. The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma. J Immunother Cancer. 2014 Jul 7;2:21. PMID: 25054064.